Who is sponsoring NCT07387159?

NCT07387159 is sponsored by Hoya Lens Rus LLC.

What drugs are being tested in NCT07387159?

Interventions in NCT07387159: MiYOSMART iQ spectacle lenses.

What condition does NCT07387159 study?

NCT07387159 studies Myopia, Child Myopia Progression.

Is NCT07387159 still recruiting?

NCT07387159 is currently recruiting now. Last updated 6 February 2026.

Last reviewed 2026-02-06 · How we verify

NCT07387159

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of MiYOSMART iQ Spectacle Lenses on Myopia Progression in Children

Recruiting now NA Last updated 6 February 2026

What this trial tests

NA trial testing MiYOSMART iQ spectacle lenses in Myopia, Child Myopia Progression in 70 participants. Currently enrolling.

Timeline

4 February 2026

Primary endpoint
31 December 2026

28 February 2027

Quick facts

Lead sponsor	Hoya Lens Rus LLC
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	70
Start date	4 February 2026
Primary completion	31 December 2026
Estimated completion	28 February 2027
Sites	1 location across Russia

Drugs / interventions tested

MiYOSMART iQ spectacle lenses

Conditions studied

Myopia, Child Myopia Progression — all drugs for Myopia, Child Myopia Progression →

Sponsor

Hoya Lens Rus LLC

Who can join

Adults 8 to 11, any sex, with Myopia, Child Myopia Progression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This prospective, single-center study aims to evaluate the efficacy and safety of MiYOSMART iQ spectacle lenses with DIMS (Defocus Incorporated Multiple Segments) and Triple Enhanced Design (TED) technology in slowing myopia progression in children aged 8-11 years. 35 children with myopia (spherical equivalent -0.5 to -6.0 D) will be prescribed MiYOSMART iQ lenses and followed for 6 months. The study will compare changes in spherical equivalent refraction and axial length against a historical control group (n=35) using ANCOVA. Secondary outcomes include measurements of peripheral refraction and contrast sensitivity at the first prescription. The study hypothesis is that wearing MiYOSMART iQ lenses for 6 months significantly slows myopia progression compared to single-vision spectacle correction.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07387159 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hoya Lens Rus LLC
Last refreshed: 6 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07387159.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing